The 2160.HK stock rallied to HK$3.89 at market close on 27 Feb 2026, a 363.10% one-day move on heavy trading that put MicroPort CardioFlow Medtech (HKSE) in the high-volume movers list. The jump followed a sharp analyst price-target lift and notable institutional position changes. Today’s intraday range was HK$3.75–HK$4.20, with volume 1,679,000.00 and visible technical overbought signals. We summarise the drivers, valuation, technicals and what the latest analyst targets mean for Hong Kong-listed MicroPort CardioFlow in HKD

Market action and volume: 2160.HK stock session summary

MicroPort CardioFlow (2160.HK) closed at HK$3.89 on the HKSE in Hong Kong. The stock opened HK$4.00, previous close was HK$0.84, day low HK$3.75 and day high HK$4.20. Reported volume was 1,679,000.00, average volume 6,924,534.00, and relative volume flagged 1.85, underlining this as a high-volume mover. Market capitalisation stands at approximately HK$395.70M, with 482,556,634 shares outstanding. The jump followed heavy intraday interest and refreshed analyst commentary that we discuss below.

Drivers and news flow behind the move: 2160.HK stock catalysts

The immediate catalyst was a broad analyst price-target revision to an average HK$7.90, with a reported range of HK$7.58–HK$8.40 per share. That revised target followed fresh coverage and reappraisal of MicroPort CardioFlow’s product adoption in China and institutional activity. Fund holdings data show net changes in large holders and mixed buying patterns across several funds. For background on the price-target update see the coverage from Nasdaq and a competitor comparison from Investing.com source source.

Valuation and fundamentals: 2160.HK stock metrics

Key fundamentals show EPS HK$0.02, reported PE 41.00, book value per share HK$4.76, price-to-book 0.15, and price-to-sales 0.94. Cash per share is HK$2.83, and the current ratio is strong at 6.94, indicating liquidity. Gross margin is 69.08% and operating margin is negative at -8.25%, reflecting ongoing investment in R&D. By comparison the Healthcare sector average PE is about 26.90, so 2160.HK trades at a premium on reported multiples but at a discount on PB. These metrics connect to today’s move and analyst re-rating debate.

Technical read: short-term momentum on 2160.HK stock

Technicals show strong momentum. RSI is 89.10 (overbought), MACD histogram is positive, ADX is 49.58 signalling a strong trend and ROC is 392.41%. Bollinger upper band sits near HK$3.05 (middle band HK$1.15). The combination of high RSI and a strong ADX implies a vigorous move that may need consolidation. Traders should note on‑balance volume and other flow indicators are not conclusively bullish, so expect volatility in the short term.

Meyka AI rating and forecast for 2160.HK stock

Meyka AI rates 2160.HK with a score out of 100. Meyka AI rates 2160.HK with a score out of 100: 68.22, grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects yearly HK$1.16, 3‑year HK$1.50, 5‑year HK$1.81, and 7‑year HK$2.29. Versus the current HK$3.89, the 12‑month model implies -70.16% downside; a 3‑year outlook implies -61.53% and a 7‑year view implies -41.08%. Forecasts are model-based projections and not guarantees. For the market’s contrasting view, analyst price targets average HK$7.90, implying +103.34% upside from HK$3.89, highlighting a sharp split between short‑term momentum and model valuations. See our company page for live updates Meyka stock page.

Final Thoughts

High-volume trading pushed 2160.HK stock to HK$3.89 on 27 Feb 2026 after a decisive analyst price-target lift. The move reflects renewed optimism on MicroPort CardioFlow’s device adoption, but fundamentals and our model give a mixed message. Reported metrics show EPS HK$0.02, PE 41.00, strong liquidity with cash per share HK$2.83 and PB 0.15. Technical indicators flag an overbought short-term market that is likely to be volatile. Analyst consensus price targets near HK$7.90 imply a possible re-rating and +103.34% upside, while Meyka AI’s 12‑month model projects HK$1.16, implying -70.16% versus today’s close. Investors should weigh the momentum-driven upside against model-based valuation caution. Monitor next earnings and product adoption data, trading volume trends, and any institutional filing updates before adjusting positions. Meyka AI provides this as AI-powered market analysis; forecasts and grades are informational and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.